Transoral robotic surgery using the Medrobotic Flex® system: the Adelaide experience

• Published in: Journal of robotic surgery Vol. 14; no. 1; pp. 109 - 113
• Main Authors: Sethi, Neeraj, Gouzos, Michael, Padhye, Vikram, Ooi, E. H., Foreman, Andrew, Krishnan, Suren, Hodge, J. C.
• Format: Journal Article
• Language: English
• Published: London Springer London 01.02.2020; Springer Nature B.V
• Subjects: Cysts; FDA approval; Hemorrhage; Human papillomavirus; Laparoscopy; Length of stay; Medicine; Medicine & Public Health; Minimally Invasive Surgery; Neck; Original Article; Pathology; Patients; Robotic surgery; Sarcoma; Surgeons; Surgery; Surgical instruments; Tonsillitis; Tumors; Urology; Australia; Robotic surgery; Oropharyngeal squamous cell carcinoma; Trans-oral surgery; Head and neck surgery
• ISSN: 1863-2483; 1863-2491
• DOI: 10.1007/s11701-019-00941-2

Transoral robotic surgery (TORS) has become an accepted treatment option for a variety of benign and malignant pathologies of the head and neck. The Medrobotics Flex ® system is a novel single port platform available as an alternative tool to current multiport robotic technology. We present the Adelaide experience with this system thus far. The Medrobotics Flex ® system was introduced in Adelaide in January 2017. Patient demographics, pathology, indication for surgery and complications are prospectively recorded for all cases. The first 20 patients are presented in this case series. 11/20 underwent surgery for malignant disease. Of these nine were diagnosed with oropharyngeal squamous cell carcinoma (OPSCC). Histopathology revealed clear margins of primary tumour excision in 8/9 patients. There were no intraoperative complications. In terms of secondary complications, one patient undergoing tonsillectomy for recurrent tonsillitis experienced a secondary haemorrhage at day 13 following operation and one patient undergoing lateral oropharyngectomy for pT3N2b tonsillar SCC sustained an oro-cervical fistula, which settled with conservative management. We have found the Medrobotic Flex ® system to be a safe, reliable tool for managing transoral surgery. The range of pathology managed with this platform, as well as the histologic outcomes presented, demonstrates efficacy in the oropharynx and posterior oral cavity for both benign and malignant disease.